Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein of -tTF
Figure 6
Antitumor effect in vivo. Upper panel: histological analysis of tumor tissues in mice treated with drugs. (a) Necrosis and thrombosis were found in tissues of mice treated with (RGD)3-tTF; (b) no necrosis and thrombosis in mice treated with TF; (c) no necrosis and thrombosis in mice treated with RGD; (d) no necrosis and thrombosis in mice treated with saline (bar = 50 μm). Middle panel: tumor necrosis after treatment. (e) Necrosis was found at 4 days after injection of (RGD)3-tTF; (f) necrosis was found at 6 days after injection of (RGD)3-tTF; (g) necrosis was found at 8 days after injection of (RGD)3-tTF; (h) no necrosis in mice treated with TF; (i) no necrosis in mice treated with RGD. Lower panel: (j) tumor volume of mice treated with drugs. The tumor volume in mice treated with (RGD)3-tTF was significantly smaller than that in mice treated with TF, RGD, or saline; there was no significant difference between tTF and RGD (***). (k) Surviving time of tumor-bearing mice. Surviving time of tumor-bearing mice treated with (RGD)3-tTF was significantly longer than that in TF or RGD groups; there was no significant difference between tTF and RGD (***).
